Cited by 571Bacterial Infections and VaccinesMicrobial infections and disease researchNeonatal and Maternal Infections

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Trotter, Caroline L, Andrews, Nick J, Kaczmarski, Edward B, Miller, Elizabeth, Ramsay, Mary E·2004·The Lancet

Open this paper in CoChat — free account

Abstract

The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(04)16725-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
Miller, E. J., SALISBURY, D. M., & Ramsay, M. E. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 483
Self-citation
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
Ramsay, M. E., Andrews, N. J., Trotter, C. L., Kaczmarski, E. B., & Miller, E. (2003) · BMJ · doi:10.1136/bmj.326.7385.365 · Cited by 409
Self-citation
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
Ramsay, M. E., Andrews, N. J., Kaczmarski, E. B., & Miller, E. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03594-7 · Cited by 337
Self-citation
Estimating Haemophilus influenzae Type b Vaccine Effectiveness in England and Wales by Use of the Screening Method
Ramsay, M. E., McVernon, J., Andrews, N. J., Heath, P. T., & Slack, M. P. (2003) · The Journal of Infectious Diseases · doi:10.1086/376997 · Cited by 172
Self-citation
Antibody Persistence and Immunological Memory at Age 4 Years after Meningococcal Group C Conjugate Vaccination in Children in the United Kingdom
Borrow, R., Goldblatt, D., Andrews, N. J., Southern, J., Ashton, L., Deane, S., Morris, R., Cartwright, K. A. V., & Miller, E. (2002) · The Journal of Infectious Diseases · doi:10.1086/344324 · Cited by 114
Self-citation

Show all 5 references

Research works printed but not linked: 1

Quarterly Communicable Disease Reports on the COVER programme for childhood immunisation

Sorted by citations

Items 101–200 of 571

Global practices of meningococcal vaccine use and impact on invasive disease
Ali, A., Jafri, R. Z., Messonnier, N. E., Tévi‐Bénissan, C., Dürrheim, D. N., Eskola, J., Fermon, F., Klugman, K. P., Ramsay, M. E., Sow, S. O., et al. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000126 · Cited by 72
Self-citation
Long-term protection after immunization with protein–polysaccharide conjugate vaccines in infancy
Rohner, G. B., & Pollard, A. J. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.14 · Cited by 69
Routinely vaccinating adolescents against meningococcus: targeting transmission & disease
Vetter, V., Baxter, R. P., Denizer, G., Sáfadi, M. A. P., Silfverdal, S., Vyse, A., & Borrow, R. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1130628 · Cited by 71
History of meningococcal vaccines and their serological correlates of protection
Vipond, C., Care, R. S., & Feavers, I. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.060 · Cited by 69
Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era
Trotter, C. L., Borrow, R., Findlow, J., Holland, A., Frankland, S., Andrews, N. J., & Miller, E. (2008) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00279-08 · Cited by 70
Self-citation
Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States
Ortega‐Sanchez, I. R., Meltzer, M. I., Shepard, C. W., Zell, E. R., Messonnier, M. L., Bilukha, O. O., Zhang, X., Stephens, D. S., & Messonnier, N. E. (2008) · Clinical Infectious Diseases · doi:10.1086/524041 · Cited by 70
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
Baxter, R. P., Baine, Y., Ensor, K., Bianco, V., Friedland, L. R., & Miller, J. M. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182054ab9 · Cited by 69
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine
Perez, J. L., Absalon, J., Beeslaar, J. F., Balmer, P., Jansen, K. U., Jones, T. R., Harris, S. L., York, L. J., Jiang, Q. L., Radley, D. R., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1483726 · Cited by 69
Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis
McMillan, M., Chandrakumar, A., Wang, H. L. R., Clarke, M. F., Sullivan, T., Andrews, R. M., Ramsay, M. E., & Marshall, H. S. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1733 · Cited by 69
Self-citation
Quadrivalent meningococcal conjugate vaccines
Pace, D., Pollard, A. J., & Messonnier, N. E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.003 · Cited by 69
Clinical experience with the meningococcal B vaccine, Bexsero ® : Prospects for reducing the burden of meningococcal serogroup B disease
Watson, P. S., & Turner, D. P. J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.057 · Cited by 68
Seroefficacy of Vi Polysaccharide–Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV)
Voysey, M., & Pollard, A. J. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1145 · Cited by 67
Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature
Balmer, P., Burman, C., Serra, L., & York, L. J. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1454570 · Cited by 68
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines
Pace, D., & Pollard, A. J. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2006.111500 · Cited by 65
Generating memory with vaccination
Castellino, F., Galli, G., Giudice, G. D., & Rappuoli, R. (2009) · European Journal of Immunology · doi:10.1002/eji.200939550 · Cited by 64
Serotype-Specific and Age-Dependent Generation of Pneumococcal Polysaccharide-Specific Memory B-Cell and Antibody Responses to Immunization with a Pneumococcal Conjugate Vaccine
Clutterbuck, E., Oh, S., Hamaluba, M., Westcar, S., Beverley, P. C. L., & Pollard, A. J. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00336-07 · Cited by 64
Combination vaccines containing DTPa–Hib: impact of IPV and coadministration of CRM197 conjugates
Dagan, R., POOLMAN, J. T., & Zepp, F. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.1.97 · Cited by 62
Reassessing the Cost-Effectiveness of Meningococcal Serogroup C Conjugate (MCC) Vaccines Using a Transmission Dynamic Model
Trotter, C. L., & Edmunds, W. J. (2006) · Medical Decision Making · doi:10.1177/0272989x05284109 · Cited by 63
Self-citation
Meningococcal glycoconjugate vaccines
Gasparini, R., & Panatto, D. (2011) · Human Vaccines · doi:10.4161/hv.7.2.13717 · Cited by 61
Designing a new antifungal glycoconjugate vaccine
Johnson, M. A., & Bundle, D. R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35382b · Cited by 62
Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of theNeisseria meningitidisSerogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan
Huo, Z., Sinha, R., McNeela, E. A., Borrow, R., Giemza, R., Cosgrove, C., Heath, P. T., Mills, K. H. G., Rappuoli, R., Griffin, G. E., et al. (2005) · Infection and Immunity · doi:10.1128/iai.73.12.8256-8265.2005 · Cited by 62
Vaccines against bacterial meningitis
Segal, S., & Pollard, A. J. (2004) · British Medical Bulletin · doi:10.1093/bmb/ldh041 · Cited by 60
Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants
Perrett, K. P., Snape, M. D., Ford, K. J., John, T. M., Yu, L., Langley, J. M., McNeil, S., Dull, P. M., Ceddia, F., Anemona, A., et al. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31818e037d · Cited by 59
The Changing Epidemiology of Meningococcal Disease
Cohn, A. C., & MacNeil, J. R. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.08.002 · Cited by 59
Long-term protection in children with meningococcal C conjugate vaccination: lessons learned
Borrow, R., & Miller, E. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.6.851 · Cited by 58
Self-citation
Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine
MacNeil, J. R., Cohn, A. C., Zell, E. R., Schmink, S. E., Miller, E. R., Clark, T. A., & Messonnier, N. E. (2011) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31820a8b3c · Cited by 58
Self-citation
Caracterización de aislamientos invasivos de S. pneumoniae, H. influenzae y N. meningitidis en América Latina y el Caribe: SIREVA II, 2000-2005
Gabastou, J.-M., Agudelo, C. I., Brandileone, M. C. D. C., Castañeda, E., de Lemos, A. P. S., & Fábio, J. L. D. (2008) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892008000700001 · Cited by 57
Meningococcal disease and climate
Palmgren, H. (2009) · Global Health Action · doi:10.3402/gha.v2i0.2061 · Cited by 56
Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine
Southern, J., Crowley-Luke, A., Borrow, R., Andrews, N. J., & Miller, E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.07.060 · Cited by 56
Self-citation
Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex
Stoof, S. P., Rodenburg, G. D., Knol, M. J., Rümke, L. W., Man-Bovenkerk, S., Berbers, G. A. M., Spanjaard, L., ENDE, A. V. D., & Sanders, E. A. M. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ506 · Cited by 56
Seroprevalence of Bactericidal and Anti-Outer Membrane Vesicle Antibodies to Neisseria meningitidis Group B in England
Trotter, C. L., Findlow, J., Balmer, P., Holland, A., Barchha, R., Hamer, N., Andrews, N. J., Miller, E., & Borrow, R. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00102-07 · Cited by 55
Self-citation
Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine Development
Pajón, R., Fergus, A. M., Koeberling, O., Caugant, D. A., & Granoff, D. M. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001302 · Cited by 54
Carbohydrate Moieties as Vaccine Candidates
Lucas, A. H., Apicella, M. A., & Taylor, C. E. (2005) · Clinical Infectious Diseases · doi:10.1086/432582 · Cited by 54
Cost-effectiveness of vaccination against meningococcal B among Dutch infants
Pouwels, K. B., Hak, E., ENDE, A. V. D., Christensen, H., van den Dobbelsteen, G. P. J. M., & Postma, M. J. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23888 · Cited by 52
A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants
Nolan, T. M., Lambert, S. B., Roberton, D. M., Marshall, H. S., Richmond, P., Streeton, C. L., POOLMAN, J. T., & Boutriau, D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.10.013 · Cited by 53
One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children
Klein, N. P., Baine, Y., Bianco, V., Lestrate, P., Naz, A., Blatter, M. M., Friedland, L. R., & Miller, J. M. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31828693c5 · Cited by 52
Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study
Perrett, K. P., McVernon, J., Richmond, P., Marshall, H. S., Nissen, M. D., August, A., Percell, S., Toneatto, D., & Nolan, T. M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.103 · Cited by 51
The kinetics and phenotype of the human B‐cell response following immunization with a heptavalent pneumococcal‐CRM197 conjugate vaccine
Clutterbuck, E., Salt, P., Oh, S., Marchant, A., Beverley, P. C. L., & Pollard, A. J. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02436.x · Cited by 51
Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection
Ali, Y. M., Hayat, A., Saeed, B. M., Haleem, K. S., Alshamrani, S., Kenawy, H. I., Ferreira, V. P., Saggu, G., Buchberger, A. M. S., Lachmann, P. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401011111 · Cited by 50
Meningococcal serogroup B vaccine: Knowledge and acceptability among parents in Italy
Morrone, T., Napolitano, F., Albano, L., & Giuseppe, G. D. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1313940 · Cited by 52
Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
Vesikari, T., Forstén, A., Boutriau, D., Bianco, V., der Wielen, M. V., & Miller, J. M. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22166 · Cited by 49
Pneumococcal conjugate vaccine and pneumococcal common protein vaccines
BLACK, S. B., Eskola, J., Whitney, C., & Shinefield, H. R. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50027-1 · Cited by 49
The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?
Maiden, M. C. J. (2013) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0147 · Cited by 47
Quality-control issues and approaches in vaccine development
Metz, B., van den Dobbelsteen, G., van Els, C. A. C. M., van der Gun, J., Levels, L., van der Pol, L., Rots, N. Y., & Kersten, G. F. A. (2009) · Expert Review of Vaccines · doi:10.1586/14760584.8.2.227 · Cited by 47
Glycoconjugate vaccines
Pace, D. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.725718 · Cited by 47
Bacterial Meningitis
Makwana, N., & Riordan, F. A. I. (2007) · CNS Drugs · doi:10.2165/00023210-200721050-00001 · Cited by 49
Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction
Ishola, D., Borrow, R., Findlow, H., Findlow, J., Trotter, C. L., & Ramsay, M. E. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05655-11 · Cited by 46
Self-citation
Waning Immunity and Microbial Vaccines—Workshop of the National Institute of Allergy and Infectious Diseases
Gu, X., Plotkin, S. A., Edwards, K. M., Sette, A., Mills, K. H. G., Levy, O., Sant, A. J., Mo, A. X. Y., Alexander, W., Lu, K. T., et al. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00034-17 · Cited by 45
Immunogenicity, Reactogenicity, and Immune Memory after Primary Vaccination with a Novel Haemophilus influenzae - Neisseria meningitidis Serogroup C Conjugate Vaccine
Schmitt, H., Maechler, G., Habermehl, P., Knuf, M., Sänger, R., Begg, N. T., & Boutriau, D. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00377-06 · Cited by 46
Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar)
Isaacman, D. J., Fletcher, M. A., Fritzell, B., Ciuryla, V. T., & Schranz, J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.09.011 · Cited by 45
Plasma cell survival: The intrinsic drivers, migratory signals, and extrinsic regulators
Nguyen, D. C., Duan, M., Ali, M., Ley, A. M., Sanz, I., & Lee, F. E.-H. (2021) · Immunological Reviews · doi:10.1111/imr.13013 · Cited by 47
Vaccine Preventable Diseases and Vaccination Coverage in Australia, 2001 to 2002
Brotherton, J., McIntyre, P., Puech, M., Wang, H., Gidding, H., Hull, B., Lawrence, G., MacIntyre, R., Wood, N., & Armstrong, D. (2004) · Communicable Diseases Intelligence · doi:10.33321/cdi.2004.28.65 · Cited by 46
Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults
Halperin, S. A., Langley, J. M., Smith, B. R., Wunderli, P. S., Kaufman, L., KIMURA, A. E., & Martin, D. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.001 · Cited by 45
Herd Protection against Meningococcal Disease through Vaccination
Clark, S. A., & Borrow, R. (2020) · Microorganisms · doi:10.3390/microorganisms8111675 · Cited by 45
Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses
Snape, M. D., Philip, J., John, T. M., Robinson, H., Kelly, S., Gossger, N., Yu, L., Kittel, C., Toneatto, D., Dull, P. M., et al. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31829cfff2 · Cited by 43
Use of Meningococcal Vaccines in the United States
Bilukha, O. O., Messonnier, N. E., & Fischer, M. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000259996.95965.ef · Cited by 43
A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 Months
Díez‐Domingo, J., Planelles, M. V., Baldó, J. M., Sansano, M. I. U., Jubert, A., Merino, Á. H., de Miguel, Á. G., González, J. B., & Marcos, M. D. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181b9a831 · Cited by 43
Quality of theHaemophilus influenzaeType b (Hib) Antibody Response Induced by Diphtheria-Tetanus-Acellular Pertussis/Hib Combination Vaccines
Denoël, P., Goldblatt, D., de Vleeschauwer, I., Jacquet, J., Pichichero, M. E., & POOLMAN, J. T. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00154-07 · Cited by 43
Meningococcal disease and prevention at the Hajj
Borrow, R. (2009) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2009.05.003 · Cited by 43
Meningococcal Disease: Epidemiology and Early Effects of Immunization Programs
Sáfadi, M. A. P., Berezin, E. N., & Falleiros-Arlant, L. H. (2014) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piu027 · Cited by 42
The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012
Sadarangani, M., Scheifele, D. W., Halperin, S. A., Vaudry, W., Saux, N. L., Tsang, R. S. W., Bettinger, J. A., Bridger, N. A., Morris, R., Halperin, S. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu597 · Cited by 42
Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil
Andrade, A. L., Minamisava, R., Tomich, L. G. M. D. M., de Lemos, A. P. S., Gorla, M. C., Brandileone, M. C. D. C., Domingues, C. M. S., de Moraes, C., Policena, G. M., Bierrenbach, A. L., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.010 · Cited by 44
Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification
Garrido‐Estepa, M., León-Gómez, I., Herruzo, R., & Cano, R. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.010 · Cited by 41
Vaccination strategies for the prevention of meningococcal disease
Vuocolo, S. C., Balmer, P., Gruber, W. C., Jansen, K. U., Anderson, A. S., Perez, J. L., & York, L. J. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1451287 · Cited by 42
Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme
Tirani, M., Meregaglia, M., & Melegaro, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123383 · Cited by 40
Identifying Optimal Vaccination Strategies for Serogroup A Neisseria meningitidis Conjugate Vaccine in the African Meningitis Belt
Tartof, S. Y., Cohn, A. C., Tarbangdo, F., Djingarey, M. H., Messonnier, N. E., Clark, T. A., Kambou, J. L., Novak, R. T., Diomandé, F. V. K., Médah, I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063605 · Cited by 40
Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil
Cardoso, C. W., Pinto, L. L. S., dos Reis, M. G., Flannery, B. L., & Reis, J. N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.044 · Cited by 39
Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody
Wang, D., Li, Z., Xiao, J., Wang, J., Zhang, L., Liu, Y., Fan, F., Lü, X., Wei, M., Kong, Z., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123944 · Cited by 39
Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study
Stoof, S. P., Heijstek, M. W., Sijssens, K. M., van der Klis, F. R. M., Sanders, E. A. M., Teunis, P. F. M., Wulffraat, N. M., & Berbers, G. A. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202561 · Cited by 39
Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy
Pace, D. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.18 · Cited by 39
Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003–2005
de Greeff, S. C., de Melker, H. E., Schouls, L. M., Spanjaard, L., & van Deuren, M. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0535-1 · Cited by 39
A framework for research on vaccine effectiveness
Crowcroft, N. S., & Klein, N. P. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.04.016 · Cited by 39
Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria
Sadarangani, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02674 · Cited by 39
A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global Control
Tzeng, Y., & Stephens, D. S. (2021) · Microorganisms · doi:10.3390/microorganisms9030519 · Cited by 39
Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis
Wals, P. D., Coudeville, L., Trottier, P., Chevat, C., Erickson, L. J., & Nguyễn, V. H. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.071 · Cited by 39
Acute Bacterial Meningitis beyond the Neonatal Period
Garcia, C. G., & McCracken, G. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00040-4 · Cited by 39
Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix™)
Croxtall, J. D., & Dhillon, S. (2012) · Drugs · doi:10.2165/11209580-000000000-00000 · Cited by 38
Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil
Tauil, M. D. C., de Carvalho, C. S. R., Vieira, A. C., & Waldman, E. A. (2014) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2013.11.012 · Cited by 38
Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
Ohm, M., Hahné, S., ENDE, A. V. D., Sanders, E. A. M., Berbers, G. A. M., Ruijs, W. L. M., van Sorge, N. M., de Melker, H. E., & Knol, M. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab791 · Cited by 39
Infections of the nervous system
Gendelman, H. E., & Persidsky, Y. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00951-2 · Cited by 38
The Role of Economic Evaluation in Vaccine Decision Making
Welte, R., Trotter, C. L., Edmunds, W. J., Postma, M. J., & Beutels, P. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523090-00001 · Cited by 38
Self-citation
Plasma and memory B‐cell kinetics in infants following a primary schedule of CRM197‐conjugated serogroup C meningococcal polysaccharide vaccine
Kelly, D. F., Snape, M. D., Perrett, K. P., Clutterbuck, E., Lewis, S., Rohner, G. B., Jones, M., Yu, L., & Pollard, A. J. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.02934.x · Cited by 37
Meningococcal conjugate vaccines: efficacy and new combinations
Sáfadi, M. A. P., & Barros, A. P. (2006) · Jornal de Pediatria · doi:10.2223/jped.1495 · Cited by 37
Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose
Klugman, K. P., Madhi, S. A., Adegbola, R. A., Cutts, F. T., Greenwood, B. M., & Hausdorff, W. P. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.089 · Cited by 36
Fast Tracking the Vaccine Licensure Process to Control an Epidemic of Serogroup B Meningococcal Disease in New Zealand
LENNON, D. R., Jackson, C. M., Wong, S., Horsfall, M., STEWART, J. M., & Reid, S. (2009) · Clinical Infectious Diseases · doi:10.1086/603552 · Cited by 36
Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile
Villena, R., Valenzuela, M. T., Bastías, M., & Santolaya, M. E. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.09.050 · Cited by 36
Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: A model-based evaluation
DeWals, P., Trottier, P., & Pépin, J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.02.010 · Cited by 36
Vaccination schedule for childhood and adolescence: comparing recommendations
Feijó, R. B., Cunha, J., & Krebs, L. D. S. (2006) · Jornal de Pediatria · doi:10.2223/jped.1498 · Cited by 35
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
Khatami, A., Snape, M. D., Davis, E., Layton, H., John, T. M., Yu, L., Dull, P. M., Gill, C. J., Odrjlin, T., Dobson, S., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.046 · Cited by 35
Meningococcal Vaccines: Current Issues and Future Strategies
Cohn, A. C., & Harrison, L. H. (2013) · Drugs · doi:10.1007/s40265-013-0079-2 · Cited by 35
Public health research literature on infectious diseases: coverage and gaps in Europe
Durando, P., Sticchi, L., Sasso, L., & Gasparini, R. (2007) · European Journal of Public Health · doi:10.1093/eurpub/ckm066 · Cited by 35
Mucosal Immunity in Healthy Adults after Parenteral Vaccination with Outer‐Membrane Vesicles fromNeisseria meningitidisSerogroup B
Davenport, V., Groves, E., Horton, R. E., Hobbs, C., Guthrie, T., Findlow, J., Borrow, R., Næss, L. M., Oster, P., Heyderman, R. S., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/590669 · Cited by 35
Epidemiologic Investigation and Targeted Vaccination Initiative in Response to an Outbreak of Meningococcal Disease among Illicit Drug Users in Brooklyn, New York
Weiss, D., Stern, E. J., Zimmerman, C. M., Bregman, B., Yeung, A., Das, D., Dentinger, C., Marx, M. A., Kornblum, J. S., Lee, L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597257 · Cited by 35
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)
Meningococcal, C. (2007) · Cited by 35
Modeling Future Changes to the Meningococcal Serogroup C Conjugate (MCC) Vaccine Program in England and Wales
Trotter, C. L., Edmunds, W. J., Ramsay, M. E., & Miller, E. (2006) · Human Vaccines · doi:10.4161/hv.2.2.2611 · Cited by 35
Self-citation
Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience
Miller, J. M., Mesaros, N. E., der Wielen, M. V., & Baine, Y. (2011) · Advances in Preventive Medicine · doi:10.4061/2011/846756 · Cited by 34
Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines
Vesikari, T., Forstén, A., Bianco, V., der Wielen, M. V., & Miller, J. M. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000897 · Cited by 34
Can we control all-cause meningococcal disease in Europe?
Sadarangani, M., & Pollard, A. J. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.03.006 · Cited by 34
Economic evaluation of meningococcal vaccines: considerations for the future
Christensen, H., Al‐Janabi, H., Lévy, P., Postma, M. J., Bloom, D. E., Landa, P., Damm, O., SALISBURY, D. M., Díez‐Domingo, J., Towse, A., et al. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01129-z · Cited by 34
Persistence of Group C Anticapsular Antibodies Two to Three Years After Immunization With an Investigational Quadrivalent Neisseria meningitidis-Diphtheria Toxoid Conjugate Vaccine
Granoff, D. M., Morgan, A., & Welsch, J. A. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000151035.64356.f8 · Cited by 34

Authors: Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E.
Affiliations: Manchester Royal Infirmary (GB)
ORCID: Trotter, Caroline L
Andrews, Nick J
Miller, Elizabeth
Ramsay, Mary E
Venue: The Lancet
Publisher: Elsevier BV
Published: 2004-07
Volume: 364
Issue: 9431
Pages: 365-367
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(04)16725-1
OpenAlex: W2160879811
Cited by: 571
References: 5
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 12 · 2019: 15 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 27 · 2013: 29 · 2012: 42
FWCI: 50.77
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Explore Bristol Research (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
Keywords: vaccine effectiveness, long-term vaccine effectiveness, herd immunity, catch-up vaccination, meningococcal disease incidence, vaccination schedule, England
MeSH terms: Adolescent, Adult, Age Factors, Child, Child, Preschool, England, Follow-Up Studies, Humans, Immunization Schedule, Immunization, Secondary, Infant, Meningococcal Infections, Vaccines, Conjugate, Meningococcal Vaccines, Immunity, Herd, Neisseria meningitidis, Serogroup C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks